Semaglutide reduces appetite and slows gastric emptying, but it does not prevent weight gain if you consume energy-dense foods in large quantities or have developed compensatory eating behaviors (like liquid calories or frequent snacking)
Sulfonylureas target ABC transporters (hsa02010), yet these were not identified in the enrichment analysis for AD or DM2, despite their role in drug metabolism, BBB permeability, and -amyloid clearance 79,80
Emerging delivery technologies Research is actively pursuing better oral peptide delivery methods
Diarrhoea is another potential concern
Key takeaways Semaglutide is indicated to treat type 2 diabetes, reduce the risk of heart attack and stroke in people with obesity or overweight, and to help lose weight and assist with chronic weight management
Nutrient injections are intended to support wellness and address documented deficiencies